Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia
Chihaya Imai, Atsushi Satō, Mitsuteru Hiwatari, Yasuto Shimomura et autres
jp (code pays fourni par la source)
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
Chihaya Imai, Atsushi Satō, Mitsuteru Hiwatari, Yasuto Shimomura et autres
jp (code pays fourni par la source)
Kohei Kawahara, Yasuto Shimomura, Yuichiro Oshima, Tadashi Watanabe et autres
Purpose: There has been limited focus on sweating failure in patients with brain tumor. We report two patients with generalized anhidrosis caused by germinoma. We also review previous reports of generalized anhidrosis due to brain tumor. Case Reports: Patient 1 was a …
jp (code pays fourni par la source)
Mitsuko Akaihata, Kenji Miyata, Yasuto Shimomura, Toshinori Hori et autres
A 9-year-old boy with acute lymphoblastic leukemia experienced a hypersensitivity reaction (HSR) and acral erythema upon receiving high-dose methotrexate (HDMTX). Both HSR and acral erythema are uncommon adverse events of MTX therapy, and MTX has not been reported to cause HSRs in …
Motoya Kimura, Yoshiteru Azuma, Soutarou Taguchi, Mizuki Takagi et autres
jp (code pays fourni par la source)
Mitsuko Akaihata, Hiroaki Somiya, Yasuto Shimomura, Toshinori Hori et autres
jp (code pays fourni par la source)
Kenji Miyata, Mitsuko Akaihata, Yasuto Shimomura, Toshinori Hori et autres
jp (code pays fourni par la source)
Shunsuke Nakagawa, Motohiro Kato, Toshihiko Imamura, Chihaya Imai et autres
Induction deaths (ID) remain a critical issue in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). The reported rate of ID in this population is 1% or higher. We speculate that this proportion might be lower in Japan because of …
jp, us (code pays fourni par la source)
Taichiro Muto, Yu Masuda, Shingo Numoto, Shunsuke Kodama et autres
We explored parameters to predicting the efficacy of intravenous immunoglobulin (IVIG) therapy for patients with Kawasaki disease (KD). We retrospectively analyzed the laboratory data of 77 children with KD treated with IVIG. Data obtained before and within 24 hours after IVIG therapy …
jp (code pays fourni par la source)
Kenji Miyata, Toshinori Hori, Yasuto Shimomura, Masahiro Joko et autres
jp (code pays fourni par la source)
Kenji Miyata, Toshinori Hori, Kiyoshi Yamakawa, Michihiko Takasu et autres
A 6-year-old girl was admitted with a mass lesion in the cerebellar vermis. She underwent subtotal tumor resection, and on immunohistopathology the tumor consisted of two different parts: typical medulloblastoma (MB) characteristics and atypical teratoid/rhabdoid tumor (AT/RT) features, despite positive integrase interactor …
jp (code pays fourni par la source)
Toshihiko Imamura, Nobutaka Kiyokawa, Motohiro Kato, Chihaya Imai et autres
Recent studies revealed that a substantial proportion of patients with high-risk B-cell precursor acute lymphoblastic leukemia (BCP-ALL) harbor fusions involving tyrosine kinase and cytokine receptors, such as ABL1, PDGFRB, JAK2 and CRLF2, which are targeted by tyrosine kinase inhibitors (TKIs). In the …
jp (code pays fourni par la source)
Kiyoshi Yamakawa, Yuka Yamagishi, Kenji Miyata, Yasuto Shimomura et autres
We encountered 2 immunocompromised children complicated by Raoultella ornithinolytica bacteremia. One had received methylprednisolone pulse therapy for IgA nephropathy, and the other had leukopenia because of chemotherapy for leukemia. Both children had no specific symptoms, and R. ornithinolytica bacteremia was identified by …
jp (code pays fourni par la source)
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.
L'essentiel de l'actu tech du Burkina & d'Afrique, chaque semaine dans votre boîte mail.
Gratuit · sans spam · désinscription en un clic